New hope for Hard-to-Treat cancers? early trial launches
Disease control
Recruiting now
This early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…
Phase: PHASE1, PHASE2 • Sponsor: Crossignal Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC